Acyclovir Lauriad®

Phase III (BA 2005/21/02) Pivotal Study, Herpes Labialis (ongoing)

Regulatory and Ethics approvals were obtained in 2007 to conduct the study in Australia, France, Germany, the United Kingdom and the Czech Republic. The purpose of this trial, conducted in patients with recurrent labial herpes (640 anticipated), is to compare acyclovir Lauriad® with a placebo. The main criterion evaluation will be the time taken to heal the herpes lesion observed for 15 days.